Drug-induced acute kidney injury;Medikamentös bedingte akute Nierenschädigung

Therapeutische Umschau

Volumn 72, Issue 11-12, 2015, Pages 717-727

  Derungs, Adrian ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; CHLORPROMAZINE; CISPLATIN; CONTRAST MEDIUM; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDRALAZINE; IFOSFAMIDE; ISONIAZID; METHYLDOPA; NONSTEROID ANTIINFLAMMATORY AGENT; PROCAINAMIDE; PROPYLTHIOURACIL; QUINIDINE; VANCOMYCIN;

ACUTE KIDNEY FAILURE; ARTICLE; BLOOD VESSEL INJURY; CHOLESTEROL EMBOLISM; GLOMERULONEPHRITIS; GLOMERULOPATHY; HUMAN; KIDNEY BIOPSY; KIDNEY INJURY; KIDNEY TUBULE DISORDER; NEPHROTOXICITY; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOTIC THROMBOCYTOPENIC PURPURA; ACUTE KIDNEY INJURY; CHEMICALLY INDUCED; DRUG SURVEILLANCE PROGRAM; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GERMANY; MEDICATION ERROR; PREVENTION AND CONTROL;

ACUTE KIDNEY INJURY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GERMANY; HUMANS; MEDICATION ERRORS; PHARMACOVIGILANCE;

EID: 84951854720     PISSN: 00405930     EISSN: 16642864     Source Type: Journal    
DOI: 10.1024/0040-5930/a000742     Document Type: Article

References (73)

1. Pazhayattil GS, Shirali AC. Druginduced impairment of renal function. Int J Nephrol Renovasc Dis. 2014; 7: 457-68.
2. Mehta RL, Pascual MT, Soroko S, et al. Spectrum of acute renal failure in the intensive care unit: the PICARD experience. Kidney Int. 2004; 66 (4): 1613-21.
3. Uchino S, Kellum JA, Bellomo R, et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA. 2005; 294 (7): 813-8.
4. Choudhury D, Ahmed Z. Drugassociated renal dysfunction and injury. Nat Clin Pract Nephrol. 2006; 2(2): 80-91.
5. Decloedt E, Maartens G. Druginduced renal injury. Continuing Medical Education. 2011; 29 (6): 252-5.
6. Gambaro G, Perazella MA. Adverse renal effects of anti-inflammatory agents: evaluation of selective and nonselective cyclooxygenase inhibitors. J Intern Med. 2003; 253 (6): 643-52.
7. Ejaz P, Bhojani K, Joshi VR. NSAIDs and kidney. J Assoc Physicians India. 2004; 52: 632-40.
8. Perazella MA, Tray K. Selective cyclooxygenase-2 inhibitors: a pattern of nephrotoxicity similar to traditional nonsteroidal anti-inflammatory drugs. Am J Med. 2001; 111 (1): 64-7.
9. Weir MR. Renal effects of nonselective NSAIDs and coxibs. Cleve Clin J Med. 2002; 69 Suppl 1: SI53-8.
10. Griffin MR, Yared A, Ray WA. Nonsteroidal antiinflammatory drugs and acute renal failure in elderly persons. Am J Epidemiol. 2000; 151 (5): 488-96.
11. Floege J, Mihatsch M, Eitner F. Thrombotische Mikroangiopathien. Nephrologe. 2008; 3 (6): 452-63.
12. Floege J. Thrombotische Mikroangiopathien. In: Lehnert H, (ed.). SpringerReference Innere Medizin. SpringerReference Medizin. Berlin, Heidelberg: Springer 2014. p. 1-3.
13. Hall AM, Bass P, Unwin RJ. Druginduced renal Fanconi syndrome. Q J Med. 2014; 107 (4): 261-9.
14. Izzedine H, Launay-Vacher V, Isnard-Bagnis C, Deray G. Drug-induced Fanconi’s syndrome. Am J Kidney Dis. 2003; 41 (2): 292-309.
15. Nissim I, Horyn O, Daikhin Y, et al. Ifosfamide-induced nephrotoxicity: mechanism and prevention. Cancer Res. 2006; 66 (15): 7824-31.
16. Ciarimboli G, Holle SK, Vollenbrocker B, et al. New clues for nephrotoxicity induced by ifosfamide: preferential renal uptake via the human organic cation transporter 2. Mol Pharm. 2011; 8 (1): 270-9.
17. Ozkok A, Edelstein CL. Pathophysiology of cisplatin-induced acute kidney injury. Biomed Res Int. 2014; Article ID 967826: 1-17.
18. Yonezawa A, Inui K. Organic cation transporter OCT/SLC22A and H(+)/organic cation antiporter MATE/SLC47A are key molecules for nephrotoxicity of platinum agents. Biochem Pharmacol. 2011; 81 (5): 563-8.
19. Sprowl JA, van Doorn L, Hu S, et al. Conjunctive therapy of cisplatin with the OCT2 inhibitor cimetidine: influence on antitumor efficacy and systemic clearance. Clin Pharmacol Ther. 2013; 94 (5): 585-92.
20. Lopez-Novoa JM, Quiros Y, Vicente L, Morales AI, Lopez-Hernandez FJ. New insights into the mechanism of aminoglycoside nephrotoxicity: an integrative point of view. Kidney Int. 2011; 79 (1): 33-45.
21. Nagai J, Takano M. Molecular aspects of renal handling of aminoglycosides and strategies for preventing the nephrotoxicity. Drug Metab Pharmacokinet. 2004; 19 (3): 159-70.
22. Smith CR, Baughman KL, Edwards CQ, Rogers JF, Lietman PS. Controlled comparison of amikacin and gentamicin. N Engl J Med. 1977; 296 (7): 349-53.
23. Smith CR, Lipsky JJ, Laskin OL, et al. Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin. N Engl J Med. 1980; 302 (20): 1106-9.
24. Lerner AM, Reyes MP, Cone LA, et al. Randomised, controlled trial of the comparative efficacy, auditory toxicity, and nephrotoxicity of tobramycin and netilmicin. Lancet. 1983; 1 (8334): 1123-6.
25. Williams PD, Bennett DB, Gleason CR, Hottendorf GH. Correlation between renal membrane binding and nephrotoxicity of aminoglycosides. Antimicrob Agents Chemother. 1987; 31 (4): 570-4.
26. Abdel-Bari A, Mokhtar MS, Sabry NA, El-Shafi SA, Bazan NS. Once versus individualized multiple daily dosing of aminoglycosides in critically ill pahttp tients. Saudi Pharm J. 2011; 19 (1): 9-17.
27. Rougier F, Ducher M, Maurin M, et al. Aminoglycoside dosages and nephrotoxicity: quantitative relationships. Clin Pharmacokinet. 2003; 42 (5): 493-500.
28. Nezic L, Derungs A, Bruggisser M, Tschudin-Sutter S, Krähenbühl S, Haschke M. Therapeutic drug monitoring of once daily aminoglycoside dosing: comparison of two methods and investigation of the optimal blood sampling strategy. Eur J Clin Pharmacol. 2014; 70 (7): 829-37.
29. Wong C, Kumar SS, Graham GG, et al. Comparing dose prediction software used to manage gentamicin dosing. Intern Med J. 2013; 43 (5): 519-25.
30. Burton ME, Brater DC, Chen PS, Day RB, Huber PJ, Vasko MR. A Bayesian feedback method of aminoglycoside dosing. Clin Pharmacol Ther. 1985; 37 (3): 349-57.
31. Fuchs A, Csajka C, Thoma Y, Buclin T, Widmer N. Benchmarking therapeutic drug monitoring software: a review of available computer tools. Clin Pharmacokinet. 2013; 52(1): 9-22.
32. Beaucaire G. Does once-daily dosing prevent nephrotoxicity in all aminoglycosides equally? Clin Microbiol Infect. 2000; 6 (7): 357-62.
33. Elyasi S, Khalili H, Dashti-Khavidaki S, Mohammadpour A. Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review. Eur J Clin Pharmacol. 2012; 68 (9): 1243-55.
34. Mergenhagen KA, Borton AR. Vancomycin nephrotoxicity: a review. J Pharm Pract. 2014; 27 (6): 545-53.
35. van Hal SJ, Paterson DL, Lodise TP. Systematic review and metaanalysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob Agents Chemother. 2013; 57 (2): 734-44.
36. Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis. 2009; 49 (4): 507-14.
37. Waineo MF, Kuhn TC, Brown DL. The pharmacokinetic/pharmacodynamic rationale for administering vancomycin via continuous infusion. J Clin Pharm Ther. 2015; 40 (3): 259-65.
38. KDIGO. Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl (2011). 2012; 2 (1): 1-138.
39. Bienholz A, Kribben A. KDIGOLeitlinien zum akuten Nierenversagen, Deutsche Übersetzung. Nephrologe. 2013; 8 (3): 247-51.
40. Thomsen HS, Morcos SK. Contrast media and the kidney: European Society of Urogenital Radiology (ESUR) guidelines. Br J Radiol. 2003; 76 (908): 513-8.
41. Harjai KJ, Raizada A, Shenoy C, et al. A comparison of contemporary definitions of contrast nephropathy in patients undergoing percutaneous coronary intervention and a proposal for a novel nephropathy grading system. Am J Cardiol. 2008; 101 (6): 812-9.
42. Susantitaphong P, Eiam-Ong S. Nonpharmacological strategies to prevent contrast-induced acute kidney injury. Biomed Res Int. 2014; Article ID 463608: 1-12.
43. Thomsen HS, Morcos SK, Barrett BJ. Contrast-induced nephropathy: the wheel has turned 360 degrees. Acta Radiol. 2008; 49 (6): 646-57.
44. Pattharanitima P, Tasanarong A. Pharmacological strategies to prevent contrast-induced acute kidney injury. Biomed Res Int. 2014; Article ID 236930: 1-21.
45. Kshirsagar AV, Poole C, Mottl A, et al. N-acetylcysteine for the prevention of radiocontrast induced nephropathy: a metaanalysis of prospective controlled trials. J Am Soc Nephrol. 2004; 15 (3): 761-9.
46. Fishbane S. N-acetylcysteine in the prevention of contrast-induced nephropathy. Clin J Am Soc Nephrol. 2008; 3 (1): 281-7.
47. Anderson JL, Adams CD, Antman EM, et al. 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/ non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013; 61 (23): e179-347.
48. Krishnan N, Perazella MA. Drug-induced acute interstitial nephritis: pathology, pathogenesis, and treatment. Iran J Kidney Dis. 2015; 9(1): 3-13.
49. von Wattenwyl T, Sandoz P. Akute interstitielle Nephritiden. Schweiz Med Forum. 2003; 3 (38): 891-7.
50. Perazella MA. Diagnosing druginduced AIN in the hospitalized patient: a challenge for the clinician. Clin Nephrol. 2014; 81 (6): 381-8.
51. Schwarz A, Krause PH, Kunzendorf U, Keller F, Distler A. The outcome of acute interstitial nehttp phritis: risk factors for the transition from acute to chronic interstitial nephritis. Clin Nephrol. 2000; 54 (3): 179-90.
52. Rossert J. Drug-induced acute interstitial nephritis. Kidney Int. 2001; 60 (2): 804-17.
53. Kshirsagar AV, Falk RJ. Treatment of acute interstitial nephritis. In: Post TW, (ed.). UpTo-Date. Waltham, MA; 2015. [Accessed 31.08.2015].
54. Loh AH, Cohen AH. Drug-induced kidney disease-pathology and current concepts. Ann Acad Med Singapore. 2009; 38 (3): 240-50.
55. Markowitz GS, Appel GB, Fine PL, et al. Collapsing focal segmental glomerulosclerosis following treatment with highdose pamidronate. J Am Soc Nephrol. 2001; 12 (6): 1164-72.
56. Markowitz GS, Fine PL, D’Agati VD. Nephrotic syndrome after treatment with pamidronate. Am J Kidney Dis. 2002; 39 (5): 1118-22.
57. Desikan R, Veksler Y, Raza S, et al. Nephrotic proteinuria associated with high-dose pamidronate in multiple myeloma. Br J Haematol. 2002; 119 (2): 496-9.
58. Bodmer M, Amico P, Mihatsch MJ, et al. Focal segmental glomerulosclerosis associated with long-term treatment with zoledronate in a myeloma patient. Nephrol Dial Transplant. 2007; 22 (8): 2366-70.
59. Neyra JA, Vaidya OU, Hendricks A, Sambandam KK. Collapsing focal segmental glomerulosclerosis resulting from a single dose of zoledronate. Nephron Extra. 2014; 4 (3): 168-74.
60. Jia N, Cormack FC, Xie B, Shiue Z, Najafian B, Gralow JR. Collapsing focal segmental glomerulosclerosis following long-term treatment with oral ibandronate: case report and review of literature. BMC Cancer. 2015; 15: 535.
61. Markowitz GS, Nasr SH, Stokes MB, D’Agati VD. Treatment with IFN-α,-β, or-γ is associated with collapsing focal segmental glomerulosclerosis. Clin J Am Soc Nephrol. 2010; 5(4): 607-15.
62. Shah HH, Patel C. Long-term response to peginterferon in hepatitis C virus-associated nephrotic syndrome from focal segmental glomerulosclerosis. Ren Fail. 2013; 35(8): 1182-5.
63. Wooley PH, Griffin J, Panayi GS, Batchelor JR, Welsh KI, Gibson TJ. HLA-DR antigens and toxic reaction to sodium aurothiomalate and D-penicillamine in patients with rheumatoid arthritis. N Engl J Med. 1980; 303 (6): 300-2.
64. Dyall-Smith D. Drug-induced lupus erythematosus. In: Oakley A, (ed.). DermNet NZ. Auckland; 2015. [Accessed 31.08.2015].
65. Perazella MA. Crystal-induced acute renal failure. Am J Med. 1999; 106(4): 459-65.
66. Perazella MA. Crystal-induced acute kidney injury (acute renal failure). In: Post TW, (ed.). UpTo-Date. Waltham, MA; 2015. [Accessed 29.08.2015].
67. Berns JS, Cohen RM, Stumacher RJ, Rudnick MR. Renal aspects of therapy for human immunodeficiency virus and associated opportunistic infections. J Am Soc Nephrol. 1991; 1 (9): 1061-80.
68. Simon DI, Brosius FC, 3rd, Rothstein DM. Sulfadiazine crystalluria revisited. The treatment of Toxoplasma encephalitis in patients with acquired immunodeficiency syndrome. Arch Intern Med. 1990; 150 (11): 2379-84.
69. Widemann BC, Adamson PC. Understanding and managing methotrexate nephrotoxicity. Oncologist. 2006; 11 (6): 694-703.
70. Roth M, Obaidat A, Hagenbuch B. OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies. Br J Pharmacol. 2012; 165 (5): 1260-87.
71. Pitman SW, Frei E, 3rd. Weekly methotrexate-calcium leucovorin rescue: effect of alkalinization on nephrotoxicity; pharmacokinetics in the CNS; and use in CNS non-Hodgkin’s lymphoma. Cancer Treat Rep. 1977; 61 (4): 695-701.
72. Crixivan. In: Arzneimittelinformation-Publikationssystem (AIPS), (electronic version). Swissmedic, Bern, Switzerland. 2015. Available at: http://www. swissmedicinfo.ch/. Accessed 01.09.2015.
73. Schnellmann RG. Toxic Responses of the Kidney. In: Klaassen CD, Watkins JB, 3rd (eds.). Casarett & Doull’s Essentials of Toxicology. New York: McGraw-Hill Medical; 2010. p. 191-201.